Elemer Piros

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) is inching closer to clearing another regulatory hurdle with respect to its cannabidiol drug Epidiolex, potentially opening up a market opportunity in Europe. What Happened The European Medicines Agency's Committee for Medicinal Products for...

Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares are advancing strongly Tuesday following the release of the results of a late-stage study of its drug candidate for allergic conjunctivitis. What Happened Aldeyra said a Phase 3 trial, dubbed ALLEVIATE, that evaluated 0.25 percent and 0.5...

Following its results for the first quarter of fiscal 2019, analysts at Cantor Fitzgerald provided an update about GW Pharmaceuticals plc (NASDAQ: GWPH). The Analyst Cantor Fitzgerald analysts Elemer Piros and Kristen Kluska reiterated the Overweight rating and $193 price target on GW...

Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks. One factor that worked in favor of the biotech space: a record number of new molecular entity approvals in 2018. Accent On...

Shares of Proteostasis Therapeutics Inc (NASDAQ: PTI) were moving higher Monday after the clinical stage biopharmaceutical company announced a worldwide exclusive license agreement with Roche Group's Genentech unit. What Happened Proteostasis Therapeutics develops therapies for the...

Less than a week after its most recent update on GW Pharmaceuticals plc (NASDAQ: GWPH), Cantor Fitzgerald lowered its price target for the stock Monday after the issuance of the company's 10-K report.  The Analyst Analyst Elemer Piros reiterated an Overweight on GW...

Global Blood Therapeutics Inc (NASDAQ: GBT) shares are trading at a nearly three-month high, with a FDA event being the catalyst. What Happened Global Blood announced Monday that the FDA has agreed to allow filing for its late-stage sickle cell disease, or SCD, candidate Voxelotor under an...

GW Pharmaceuticals plc (NASDAQ: GWPH) Epidiolex drug and earlier-stage programs Sativex and CBDV will represent major catalysts for the stock in the near-term, in Cantor Fitzgerald's view.  The Analyst Analyst Elemer Piros reiterated an Overweight on GW Pharmaceuticals with a $211 price...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) stock tanked 15 percent Thursday after the company announced a new $3.7-billion deal to license its ARO-HBV treatment for chronic hepatitis B to Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals. Investors clearly weren’t...

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) earned another bullish analyst this week with a positive rating from Cantor Fitzgerald. The coverage comes with a valuation that implies 459-percent upside. The Rating Analyst Elemer Piros initiated coverage of Galmed Pharmaceuticals with an...

The first gene therapy treatment ever approved in the U.S. comes with a steep price tag. On Wednesday, Spark Therapeutics Inc (NASDAQ: ONCE) announced it will charge $425,000 per eye for one-time treatments of a rare genetic retinal disease that causes blindness. The new therapy could be a huge...

Glaukos Corp (NYSE: GKOS) announced the submission of a pre-market approval application for its iStent inject device on Wednesday. The Analyst Cantor Fitzgerald's Elemer Piros maintains an Overweight rating on Glaukos' stock with a price target boosted from $48 to $60. The Thesis...

Spark Therapeutics Inc (NASDAQ: ONCE) reported during the ASH conference an update concerning its SPK-8011 therapy, which has many investors concerned. The Analyst Cantor Fitzgerald's Elemer Piros maintains an Overweight rating on Spark Therapeutics's stock with an unchanged $105 price...

bluebird bio Inc (NASDAQ: BLUE) reported compelling data over the weekend at the American Society of Hematology that some experts described as "unheard of." The Analyst Cantor Fitzgerald's Elemer Piros reiterated an Underweight on bluebird's stock with a price target...

Omeros Corporation (NASDAQ: OMER) shares are on a tear, the catalyst being the release of its third-quarter results. The Analyst Cantor Fitzgerald's Elemer Piros, Ph.D, reviewed Omeros' quarterly results. The Rating The firm maintained its Neutral rating and 12-month price target of $19...